Kornimate/medical-research-clean huggingface dataset:
efficacy of zinc l-carnosine mouth rinse

Conditions: Periodontal Index; Pain

Summary: a clinical trial to assess the effect of a zinc-l-carnosine-based mouth rinse on periodontal tissues and pain after scaling and root planing

a randomized, double blind, 3 group parallel study with random allocation of 75 patients to any of three groups; zinc-l-carnosine-based mouth rinse, chlorhexidine mouth rinse and placebo (water) control. three days after professional oral hygiene, which aimed at the normalization of the periodontal index, the primary (hi, vas) and secondary (msbi; fmps; vmi; si) outcomes of the study are measured to obtain baseline information, and then scaling and root planing are carried out. the participants will be advised to follow their regular oral hygiene procedures (tooth brushing) in addition to the allocated mouth rinse. they will be examined again for primary and secondary outcomes at 7 and 21 days. clinical evaluation: clinical examination of each participant will be done by a single examiner using the previously described vas scale and a unc periodontal probe (no. 5 explorer hu-friedy, chicago, ill). in addition to these indices, each subject will be asked to report any adverse events they have encountered during the experiment.

Eligibility criteria:
inclusion criteria: * patients with a psr score greater than 2 that undergo a session of scaling and root planing exclusion criteria: * use of mouth rinses or local or general medication in the preceding three weeks * any condition related with allergy or sensitivity with the mouth rinses ingredients * systemic and chronic diseases in progress

Keywords: periodontal index pain
pre-procedure planning for liver biopsy or radiofrequency ablation using ct or mr/us fusing imaging

Conditions: Liver Mass; Liver Fibroses

Summary: the purpose of this study is to determine whether fusion technique of preradiofrequency ablation (rfa) or percutaneous liver biopsy cross-sectional imaging (ct or mr) and real-time ultrasonography would improve feasibility of rfa or liver biopsy in patients with liver tumor in comparison with ultrasonography guidance alone. and assessment of a new point shear-wave elastography method (pswe, s-shear wave) and compare its accuracy in assessing liver stiffness (ls) with another pswe technique (arfi).

rfa is one of commonly used local therapies for primary or secondary liver tumors. and percutaneous liver biopsy is very important technique to confirm the diagnosis of focal hepatic lesion whether benign or malignancy. for successful and safe procedure, safe access route and lesion visibility are essential , and the conditions are usually evaluated on pre-procedure planning ultrasonography (usg). however, these procedure is sometimes aborted due to limited sonic window of various cause and challenging identification of small isoechoic tumors or hepatocellular carcinomas among dysplastic nodules . therefore, precise targeting and assuring safe route would be of clinical importance. in this preliminary study, investigators attempted to determine us and ct/mr fusion technique would be able to improve rfa or liver biopsy feasibility in patients with liver tumors in comparison with conventional us alone technique. in addition, to assess intra- and inter-observer reproducibility of a new point shear-wave elastography method (pswe, s-shear wave) and compare its accuracy in assessing liver stiffness (ls) with another pswe technique (arfi).

Eligibility criteria:
inclusion criteria: * all conditions should be satisfied for inclusion. * referred to radiology in our institution for liver tumor rfa or percutaneous liver biopsy * available pre-procedure liver ct or liver mr imaging within 6 weeks exclusion criteria: * any contraindication of liver rfa or percutaneous liver biopsy • any patients who received treatment between pre-rfa imaging and planned rfa.

Keywords: fusion ablation percutaneous biopsy shear wave elastography
alpha lipoic acid in pediatrics on hemodialysis

Conditions: Hemodialysis Complication; Pediatric Kidney Disease; Cardiovascular Complication

Summary: the goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. the main questions it aims to answer are: * will the use of alpha lipoic acid lower cardiovascular events in that population? * is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population? * will the drug cause side effects? participants will: * take either one dose daily of 600mg tablet alpha lipoic acid orally or a look-alike tablet containing no drug. * be monitored for the occurrence of cardiovascular events (stroke, angina, etc.) * be monitored for the occurrence of side effects * give blood samples for testing serum levels of e-selectin biomarker and superoxide dismutase enzyme * undergo clinical examinations (echocardiogram, duplex ultrasonography, intima-media-thickness) researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.

a double-blinded, paralleled, randomized, placebo-controlled clinical trial will be conducted at the pediatric nephrology and dialysis unit, children's hospital, ain shams university, cairo, egypt to detect the efficacy of alpha lipoic acid in reducing cardiovascular events by reducing oxidative stress-mediated endothelial dysfunction in pediatric population on regular hemodialysis by assessment of: 1. e-selectin as an endothelial biomarker 2. sod as an oxidative stress biomarker 3. indicators of cvs dysfunction by; * duplex ultrasonography * echocardiogram with stress on ejection fraction * intimal medial thickness 4. occurrence of cvs events

Eligibility criteria:
inclusion criteria: * pediatric participants admitted to pediatric hemodialysis unit for regular hemodialysis. * the ability to swallow capsules will be enrolled in the study. exclusion criteria: * participants who suffered from severe congestive heart failure * participants suffering from inflammatory diseases or other diseases that may increase oxidative stress. * participants taking supplements that decrease oxidative stress or inflammatory markers * participants with hypersensitivity to alpha lipoic acid * participants who are non-compliant.

Keywords: alpha lipoic acid alpha-lipoic acid thioctic acid hemodialysis e-selectin eselectin children kidney
efficacy and safety of nitazoxanide 600 mg to treat mild ambulatory covid-19 patients

Conditions: covid19

Summary: the aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild covid-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only.

the aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild covid-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only. after 7 days of treatment, the investigator can extend the treatment duration for another 7 days at his/her discretion.

Eligibility criteria:
inclusion criteria: * informed consent from patient or legal representative. * subject of both genders (male and female not pregnant and not breastfeeding) aged over 49; * laboratory confirmation of 2019-ncov infection by reverse-transcription polymerase chain reaction (rt-pcr) from any diagnostic sampling source; * symptomatic subject with symptoms for up to 72 hours who does not require hospitalization, with signs and symptoms of acute respiratory viral infection characterized by a feverish sensation or fever, which may or may not be present at the time of the examination (which may be reported to the health professional), accompanied by cough or sore throat or runny nose or difficulty breathing and: i) oxygen saturation ≥ 90%; ii) risk classification for covid-19 between low (a) or medium (b) (scores 1 to 19), according to the brazilian ministry of health. exclusion criteria: * participating in another rct in the past 12 months; * presence of comorbidities, which have a contraindication to the use of the study product, not being restricted to: * hiv or htlv virus infection; * chronic hepatitis c (hcv) treated with direct antiviral drugs; * liver failure; * severe renal failure, including dialysis; * present hypersensitivity to the study product (nitazoxanide), as well as to related compounds; * concomitant administration of drugs that may interact with the product under study (nitazoxanide); * participants who underwent treatment with other antiviral drugs; * subject in antineoplastic treatment with chemotherapy or radiation therapy; * subject with severe autoimmune diseases in immunosuppression; * transplanted participants; * pregnant or lactating women; * any other clinical condition that is deemed by the investigator to be an imminent risk to the health and life of the subject.
economic evaluation german drug-eluting stent registry

Conditions: Coronary Heart Disease

Summary: since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients. drug-eluting stents are specifically designed to prevent the problem of in-stent restenosis. they consist of a selective anti-proliferative drug, sirolimus, a controlled-release polymer, and a closed-cell stent delivery platform. upon placement, sirolimus elutes into the vessel wall and stops the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis. the study "economic evaluation of the german drug-eluting stent registry" examines the cost-effectiveness of drug-eluting stents compared to bare-metal stents (bms) in patients with coronary stenosis. the goal of the study is to examine whether the guideline-supported implantation of ses, despite the higher initial cost, improves the quality and economic outcomes of the treatment of patients with coronary stenosis. secondarily, the study evaluates patient quality of life, impairment of daily activities, and re-intervention rates.


Eligibility criteria:
inclusion criteria: * indication for coronary stent implantation * additional inclusion criteria bms cohort: * acute coronary syndrome * diabetes mellitus * previous percutaneous coronary intervention/coronary artery bypass graft * 3-vessel disease

Keywords: coronary heart disease chd stent
modified tarsorrhaphy vs gold weight implant for paralytic lagophthalmos in leprosy patients

Conditions: Paralytic Lagophthalmos; Leprosy--Patients

Summary: this study aims to compare the effectivity and efficiency of modified tarsorrhaphy (mt) technique and gold weight implant (gwi) technique as a surgical treatment of paralytic lagophthalmos in leprosy patients. the hypothesis is that mt technique is more effective and more efficient than gwi technique. this study used probe (prospective randomized open-label blinded-endpoint) clinical trial. samples consisted of 14 eyes in mt group and 13 eyes in gwi group as the control group. this study was conducted in 3 hospitals in indonesia and the patients were observed in 1 year period.


Eligibility criteria:
inclusion criteria: * paucibacillary (pb) or multibacillary (mb) type leprosy patient with unilateral/bilateral lagophthalmos who had not undergone eyelid reconstruction * patient aged 18 years old or older who could be performed surgery with local anesthesia exclusion criteria: * patient with acute leprosy reaction (\<6 months) and in steroid medication * patient with eyelid laxity \>8 mm

Keywords: hansen disease leprosy paralytic lagophthalmos surgical intervention
potassium titanyl phosphate laser versus pulsed dye laser for rosacea - a prospective study

Conditions: Rosacea

Summary: to compare the efficacy and safety of 532 nm ktp and 585 nm pdl for treating rosacea.

rosacea is a common, chronic inflammatory skin disease that usually affects the cheeks, nose, forehead, and chin \[1\]. clinically, it presents initially with transient erythema (flushing) and telangiectasia. as it progresses, persistent erythema and papules and pustules appear. phymatous changes result from hypertrophy of the sebaceous glands, and usually manifest as rhinophyma, gnatophyma, and metophyma \[2\]. depending on the literature, rosacea has a prevalence of 1% to 22% \[3\]. time of manifestation of the disease is usually between 30 and 50 years \[4\]. women are more frequently affected \[4\]. for laser treatment of rosacea, the pulsed dye laser (pdl) with a wavelength of 595nm is frequently used. the treatment includes at least three sessions at intervals of about 4 weeks and leads to lightening and reduction of the lesions as well as reduction of papules and pustules. various clinical studies have already demonstrated the high efficacy of pdl \[5-7\]. the treatment is painless, and local or general anesthesia is not necessary. the ktp laser is also an option in the treatment of rosacea. due to the more stable technology of the frequency-doubled nd:yag (ktp) and associated lower maintenance problems, this laser system appears to be a safer and more reliable treatment option for rosacea patients.

Eligibility criteria:
inclusion criteria: * men and women 18 years and older * good general health, no relevant previous diseases * presence of rosacea * cognitive ability and willingness to give consent (informed consent) exclusion criteria: * age \< 18 years * pregnant and breastfeeding women * significant open wounds or lesions of the region to be treated * metallic implants in the region to be treated * missing consent and/or data protection declarations
comparison of aqueous and plasma glucose level in diabetic patients

Conditions: Diabetes Mellitus

Summary: comparison of aqueous and plasma glucose level in diabetic patients high glucose concentrations in aqueous humor are thought to be related of diabetic ocular injury, including cataract and diabetic keratopathy. the primary mechanisms are nonenzymatic glycation, oxidative stress and activation of polyol pathway. however, glucose concentrations in aqueous humor of diabetic patients was only examined in a few patients in the past. this study will compare glucose concentration in blood plasma and aqueous humor in diabetic patients undergoing cataract surgery. perioperative hemoglobin a1c concentrations will also be examined. correlation between these parameters will be analyzed.


Eligibility criteria:
inclusion criteria: - diabetic patients planed for elective cataract surgery exclusion criteria: * s/p traumatic eye injury * past or current uveitis * patients using prescription eye drops except lubricants

Keywords: diabetes mellitus, cataract, aqueous humor
trial comparing near versus distance activities while patching for amblyopia in children 3 to <7 years old

Conditions: Amblyopia

Summary: ths purpose of this study is to determine whether "near" activities enhance the effect of patching on visual acuity improvement in strabismic and anisometropic amblyopia when compared with "distance" activities in the treatment of moderate amblyopia and severe amblyopia in children 3 to \<7 years old.

the value of "near visual activities" while patching for amblyopia is controversial. some pediatric eye care providers currently recommend that the child perform near visual tasks while wearing a patch over the sound eye, while other pediatric eye care providers do not prescribe any specific visual tasks to be performed while the patch is worn. in previous randomized studies of patching doses for amblyopia conducted by the pediatric eye disease investigator group, near visual activities were incorporated into the prescribed treatment regimes. although different doses of patching, combined with near visual activities, were successful in improving visual acuity in most children, it is unclear whether concurrent near visual activities enhanced the effect of patching. this study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. the study has been designed as a simple trial that, other than the type of amblyopia therapy being determined through the randomization process, approximates standard clinical practice. the two treatment regimens for the 17 week treatment period are: 1) 2 hours of daily patching combined with near visual activities while patching and 2)2 hours of daily patching combined with distance visual activities while patching.

Eligibility criteria:
inclusion criteria: * patients must be 3 to less than 7 years old with amblyopia due to strabismus, anisometropia, or both. * visual acuity in the amblyopic eye must be between 20/40 and 20/400 inclusive, visual acuity in the sound eye 20/40 or better and inter-eye acuity difference \> 3 logmar lines. * spectacles, if needed, must be worn for at least 16 weeks or until visual acuity documented to be stable. exclusion criteria: * prior amblyopia treatment other than spectacles in the past month. * more than one month of amblyopia treatment in the past 6 months.

Keywords: amblyopia patching visual activities
one-year outcomes by index treatment in elderly patients with acute cholecystitis

Conditions: Acute Cholecystitis

Summary: background: the goldeneye study is an international, multicenter, prospective observational investigation designed to compare the outcomes of various management strategies for acute cholecystitis in patients aged 70 years and older. this research is driven by the increasing prevalence of gallstones and biliary tract diseases in the elderly, alongside a recognition that the burden of comorbidity in this population may necessitate tailored treatment approaches to optimize outcomes. patients and methods: the primary aims of the study are to evaluate the efficacy of different treatments -supportive care, percutaneous gallbladder drainage, early or delayed cholecystectomy, and eus-guided gallbladder drainage- on patient-centric outcomes, including one-year additional treatment modalities, hospital readmissions, outpatient encounters, quality of life, and survival rates. the study adopts a robust design incorporating propensity score matching analysis to account for the non-randomized allocation of treatment modalities, thereby minimizing selection bias and enhancing the comparability of treatment groups. inclusion criteria are centered on patients ≥70 years diagnosed with acute cholecystitis, as per the tokyo guidelines, while key exclusion criteria include prior episodes of cholecystitis or pancreatitis, terminal illness, and concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy. data collection will leverage the redcap platform for systematic and secure data management, facilitating real-time data entry and monitoring across participating centers. discussion: this comprehensive approach ensures the integrity and reliability of data collected on demographics, gender, clinical outcomes, and quality of life measures. through its innovative design and methodology, the goldeneye study aims to generate evidence-based insights that will significantly influence the management of acute cholecystitis in the elderly, ultimately improving patient outcomes and healthcare practices in this growing demographic population.


Eligibility criteria:
inclusion criteria: * patients ≥70 years * diagnosed with acute cholecystitis, as per the tokyo guidelines exclusion criteria: * prior episodes of cholecystitis or pancreatitis * terminal illness * concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy

Keywords: laparoscopic cholecystectomy conservative treatment drainage endosonography propensity score retrospective studies
evaluation of salbutamol as an adjuvant therapy for pompe disease

Conditions: Pompe Disease

Summary: evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset pompe disease under enzyme replacement therapy


Eligibility criteria:
inclusion criteria: 1. confirm diagnosis as pompe disease 2. age 2 years or above 3. under at least 1 year regular recombinant human acid alpha glucosidase, and no dosage/frequency change in recent 3 months 4. provide inform consent exclusion criteria: 1. chronic heart disease such as arrhythmia, cardiomyopathy, cardiac infarction 2. history of seizure 3. history of diabetes mellitus 4. history of hyperthyroidism 5. hypokalemia 6. pregnant 7. allergy to β-agonists 8. under medications including diuretics, digoxin, beta-blockers, etc
a longitudinal, multi-center safety study of autologous adult adipose-derived regenerative cell injection into chronic partial-thickness rotator cuff tears

Conditions: Partial Thickness Rotator Cuff Tear

Summary: this is a longitudinal follow-up study of the rc-002 study, in which up to 246 subjects assigned to two randomization arms will be enrolled: an adipose-derived regenerative cell (adrc) injection arm (adrc treatment arm) and the soc corticosteroid injection arm (active control arm). all subjects will be randomly assigned to adrc treatment or active control arms in a 2:1 ratio and will be followed up for 6 months. the goal of the rc-004 study is to enroll all patients that were enrolled and treated in rc-002 and follow for 3 years.


Eligibility criteria:
inclusion criteria: * 1. subjects must have completed rc-002. * 2. subjects can give appropriate consent. exclusion criteria: * 1. subjects who require the use of index arm for ambulation or mobilization via wheelchair, walker, crutches or cane. * 2. subjects whose pain behavior or pain medication usage is, in the opinion of the investigator, out of proportion to the underlying clinical condition or could interfere with the study-required assessments. * 3. subject is on an active regimen of chemotherapy or radiation-based treatment. * 4. subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give informed consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. this may include individuals with a mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention. * 5. uncooperative subjects or those with neurological/psychiatric disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.